FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313557638> ?p ?o ?g. }

• W4313557638 endingPage "548" @default.
• W4313557638 startingPage "543" @default.
• W4313557638 abstract "Advanced ovarian cancer has a poor prognosis, with a 5 year survival probability of <30%. Attempts to improve survival have focused on debulking surgery and systemic therapy. We assessed the evolution of treatment patterns and survival of patients with advanced epithelial ovarian cancer with specific attention to changes in survival after introducing bevacizumab.Population based data from the Belgian Cancer Registry were coupled with administrative reimbursement data from the compulsory health insurance organizations and the national database where date of death is registered, based on the patient's unique national number. Patients with epithelial ovarian cancer stage IV diagnosed in 2004-17 were included. The proportion of patients who underwent debulking surgery and received bevacizumab was calculated per incidence year. Survival was compared for the three incidence periods (2004-08, 2009-13, 2014-17) and before and after the introduction of bevacizumab.2034 patients with stage IV epitheial ovarian cancer were included. From 2012 onwards, uptake of bevacizumab increased, with 50% of patients with stage IV ovarian cancer diagnosed in 2017 receiving bevacizumab. The proportion of stage IV patients who underwent debulking surgery also increased over time, from 21.1% in 2004-08 to 50.4% and 45.4% in 2009-13 and 2014-17, respectively. The 3 year observed survival probability fluctuated between 27% and 42% without a trend over time. The increase in debulking surgery was associated with improved survival (hazard ratio (HR) 0.88, 95% confidence interval (CI) 0.79 to 0.98) but the introduction of bevacizumab was not (HR 0.94, 95% CI 0.85 to 1.03). For patients diagnosed in 2004, the mean cost per patient treated with oncological drugs was about €12 500, which doubled to about €25 000 for patients diagnosed in 2014 or later.Despite a rise in the use of debulking surgery and the introduction of bevacizumab into clinical practice, no improvement in 3 year survival probability was observed for patients with advanced ovarian cancer in Belgium." @default.
• W4313557638 created "2023-01-06" @default.
• W4313557638 creator A5006772768 @default.
• W4313557638 creator A5024764499 @default.
• W4313557638 creator A5031086992 @default.
• W4313557638 creator A5034050655 @default.
• W4313557638 creator A5034807071 @default.
• W4313557638 creator A5041293117 @default.
• W4313557638 creator A5044999370 @default.
• W4313557638 creator A5046579736 @default.
• W4313557638 creator A5075031778 @default.
• W4313557638 date "2023-01-05" @default.
• W4313557638 modified "2023-09-25" @default.
• W4313557638 title "Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumab" @default.
• W4313557638 cites W2057138934 @default.
• W4313557638 cites W2076494316 @default.
• W4313557638 cites W2102306754 @default.
• W4313557638 cites W2106767659 @default.
• W4313557638 cites W2113122060 @default.
• W4313557638 cites W2113631881 @default.
• W4313557638 cites W2116183806 @default.
• W4313557638 cites W2168893449 @default.
• W4313557638 cites W2170928115 @default.
• W4313557638 cites W2171658624 @default.
• W4313557638 cites W2438866487 @default.
• W4313557638 cites W2590203295 @default.
• W4313557638 cites W2775269156 @default.
• W4313557638 cites W2943306812 @default.
• W4313557638 cites W2951714360 @default.
• W4313557638 cites W3041047318 @default.
• W4313557638 cites W3207702660 @default.
• W4313557638 doi "https://doi.org/10.1136/ijgc-2022-003813" @default.
• W4313557638 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36604121" @default.
• W4313557638 hasPublicationYear "2023" @default.
• W4313557638 type Work @default.
• W4313557638 citedByCount "0" @default.
• W4313557638 crossrefType "journal-article" @default.
• W4313557638 hasAuthorship W4313557638A5006772768 @default.
• W4313557638 hasAuthorship W4313557638A5024764499 @default.
• W4313557638 hasAuthorship W4313557638A5031086992 @default.
• W4313557638 hasAuthorship W4313557638A5034050655 @default.
• W4313557638 hasAuthorship W4313557638A5034807071 @default.
• W4313557638 hasAuthorship W4313557638A5041293117 @default.
• W4313557638 hasAuthorship W4313557638A5044999370 @default.
• W4313557638 hasAuthorship W4313557638A5046579736 @default.
• W4313557638 hasAuthorship W4313557638A5075031778 @default.
• W4313557638 hasConcept C120665830 @default.
• W4313557638 hasConcept C121332964 @default.
• W4313557638 hasConcept C121608353 @default.
• W4313557638 hasConcept C126322002 @default.
• W4313557638 hasConcept C141071460 @default.
• W4313557638 hasConcept C143998085 @default.
• W4313557638 hasConcept C146357865 @default.
• W4313557638 hasConcept C151730666 @default.
• W4313557638 hasConcept C207103383 @default.
• W4313557638 hasConcept C2776283816 @default.
• W4313557638 hasConcept C2776694085 @default.
• W4313557638 hasConcept C2777802072 @default.
• W4313557638 hasConcept C2778527826 @default.
• W4313557638 hasConcept C2780427987 @default.
• W4313557638 hasConcept C2781100745 @default.
• W4313557638 hasConcept C2908647359 @default.
• W4313557638 hasConcept C44249647 @default.
• W4313557638 hasConcept C61511704 @default.
• W4313557638 hasConcept C71924100 @default.
• W4313557638 hasConcept C86803240 @default.
• W4313557638 hasConcept C99454951 @default.
• W4313557638 hasConceptScore W4313557638C120665830 @default.
• W4313557638 hasConceptScore W4313557638C121332964 @default.
• W4313557638 hasConceptScore W4313557638C121608353 @default.
• W4313557638 hasConceptScore W4313557638C126322002 @default.
• W4313557638 hasConceptScore W4313557638C141071460 @default.
• W4313557638 hasConceptScore W4313557638C143998085 @default.
• W4313557638 hasConceptScore W4313557638C146357865 @default.
• W4313557638 hasConceptScore W4313557638C151730666 @default.
• W4313557638 hasConceptScore W4313557638C207103383 @default.
• W4313557638 hasConceptScore W4313557638C2776283816 @default.
• W4313557638 hasConceptScore W4313557638C2776694085 @default.
• W4313557638 hasConceptScore W4313557638C2777802072 @default.
• W4313557638 hasConceptScore W4313557638C2778527826 @default.
• W4313557638 hasConceptScore W4313557638C2780427987 @default.
• W4313557638 hasConceptScore W4313557638C2781100745 @default.
• W4313557638 hasConceptScore W4313557638C2908647359 @default.
• W4313557638 hasConceptScore W4313557638C44249647 @default.
• W4313557638 hasConceptScore W4313557638C61511704 @default.
• W4313557638 hasConceptScore W4313557638C71924100 @default.
• W4313557638 hasConceptScore W4313557638C86803240 @default.
• W4313557638 hasConceptScore W4313557638C99454951 @default.
• W4313557638 hasIssue "4" @default.
• W4313557638 hasLocation W43135576381 @default.
• W4313557638 hasLocation W43135576382 @default.
• W4313557638 hasOpenAccess W4313557638 @default.
• W4313557638 hasPrimaryLocation W43135576381 @default.
• W4313557638 hasRelatedWork W2042861937 @default.
• W4313557638 hasRelatedWork W2072213084 @default.
• W4313557638 hasRelatedWork W2148187838 @default.
• W4313557638 hasRelatedWork W2188871454 @default.
• W4313557638 hasRelatedWork W2911758317 @default.

• next